C
CAGE Bio
CAGE Bio Inc. - Ionic Liquids, Biotech, Pharmaceutical
About CAGE Bio
CAGE Bio Inc. is a clinical-stage biotechnology firm founded in 2016 by Samir Mitragotri and Ravi Srinivasan, with Nitin Joshi joining as a co-founder and CEO in 2018. The company operates in the pharmaceutical sector, specifically focusing on developing therapies for dermatology, inflammation, and immunology. Its business model centers on the development and commercialization of prescription therapeutics and consumer healthcare products. CAGE Bio generates revenue through upfront payments, milestone payments, and royalties from licensing agreements with other biotechnology companies.
The company was established to leverage an ionic liquid platform technology originally invented by co-founder Samir Mitragotri, a Professor of Bioengineering at Harvard University, and his team at the University of California, Santa Barbara. This technology addresses significant challenges in dermatological drug delivery. Nitin Joshi, the CEO, brings over two decades of experience in drug development and has led products through regulatory approval in the U.S. and E.U. at companies like Elan, Alkermes, and ALZA (J&J). His journey includes co-founding Incline Therapeutics, which was later acquired, demonstrating a track record of advancing pharmaceutical technologies to market. Since its inception, CAGE Bio has raised $17.8 million in funding over two rounds. A significant Series A funding round in February 2021, which raised $7.2 million, is enabling the company to advance its clinical programs.
CAGE Bio's core service is its proprietary deep eutectic ionic liquid platform. This technology uses liquid salts that can enhance the solubility and skin permeability of various drug molecules, including small molecules, peptides, proteins, and nucleic acids. The platform enables the localized, topical delivery of potent drugs directly to the affected tissue, which can improve efficacy while minimizing the side effects associated with systemic exposure. One of the lead products, CGB-500, is a topical treatment for atopic dermatitis. In a 2023 Phase 2a clinical trial, CGB-500 demonstrated a 98% improvement in the disease severity index compared to a 28% improvement in the placebo group. Following these results, a larger Phase 2b trial with 180 participants was initiated in January 2025 to optimize dosing and further evaluate safety and efficacy. Another product, CGB-400, is being developed for papulopustular rosacea and entered Phase 2 trials in May 2021.
Source: Dealroom company dataNews
Open roles
CAGE Bio in the San Carlos ecosystem
The CAGE Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Propel(x)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CAGE Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CAGE Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


